Treatment options in chronic lymphocytic leukemia (CLL) – a Polish perspective
Journal Title: JOURNAL OF HEALTH POLICY & OUTCOMES RESEARCH - Year 2018, Vol 1, Issue 1
Abstract
Chronic lymphocytic leukemia (CLL) is the most frequent type of leukemia among the elderly people in Western societies. CLL is genetically and molecularly heterogeneous disease that translates into clinical outcomes. Currently, the most unfavorable prognosis is associated with the presence of deletion of the short arm of chromosome 17 (del17p) and/or mutation of the TP53 gene (mTP53) that requires an individualized therapeutic approach. Allogenic hematopoietic stem cells transplantation (allo-HSCT) is still the only potentially curative treatment option in patients with CLL. Nevertheless, it is associated with high toxicity and treatment-related mortality. Therefore, it can be used only in selected patients, mostly young and fit without significant comorbidities. Moreover, allo-HSCT should be performed in patients who achieve disease remission. Recent advances in molecular biology have led to the better understanding of CLL pathophysiology and development of new targeted therapies. Recently developed and approved drugs such as new anti-CD20 monoclonal antibodies (obinutuzumab, ofatumumab), B-cell receptor inhibitors (BCRi) (ibrutinib, idelalisib) and B-cell lymphoma 2 (BCL-2) protein inhibitor (venetoclax) provide better clinical outcomes in CLL patients than previously used standard chemotherapy regimens. Most of those new drugs have been included in treatment algorithms described in Polish, European and global clinical practice guidelines. However, not all of them are available for Polish patients due to the lack of reimbursement, leaving them in the clinical unmet need state. This review summarizes recent advances in CLL treatment, focusing on the Polish perspective.
Authors and Affiliations
Magdalena Monica, Anita Stożek-Tutro, Iwona Hus
Keywords
Related Articles
- EP ID EP532088
- DOI 10.7365/JHPOR.2018.1.3
- Views 70
- Downloads 0
Contracts for providing publically funded outpatient medical services - criteria for tenders evaluation as a tool of health policy in Poland
he Polish health care system is essentially divided into three basic levels of service: basic health care, outpatient specialist care, hospital treatment. Since 2003 the payer is the National Health Fund. Medical facilit...
Protection of sensitive data in telemedicine services
The article presents security risks related to the use of telemedicine services and technical guidelines for protection of the medical records in terms of their confidentiality, integrity and availability. It also mentio...
Primary immunodeficiencies – epidemiology, spending on therapy, diagnostic and therapeutic needs in Poland
Abstract Primary immunodeficiencies (PID) are a heterogeneous group of over 300 diseases of the immune system characterised by its disfunction, and in consequence by chronic or recurrent infections, autoimmunity, aller...
The access to an ophthalmic treatment in Poland on the example of the ocular complications in the course of diabetes mellitus
Background Diabetic Retinopathy (DR) is the severe disease, that develops as a result of diabetes complication. All diabetic patients are at risk of DR development and the National Health Fund (NHF) estimates that ther...
Pharmaceutical system in Ukraine: current and prospective issues
ntroduction: To review the current pharmaceutical system in the private and public sectors in Ukraine in terms of the availability and affordability of medicines, to explore and analyze national health system reforms sta...